What is causing the significant decrease in net earnings for the first half of 2002?

The significant decrease in net earnings is primarily due to a substantial decline in sales, driven by the ongoing workdown of U.S. wholesaler inventory levels and increased generic competition for key pharmaceutical products such as GLUCOPHAGE IR, TAXOL, and BUSPAR. Additionally, the company incurred significant expenses related to litigation and made substantial income tax payments.

How is the company addressing the U.S. wholesaler inventory issue?

Bristol-Myers Squibb has made substantial progress in reducing U.S. wholesaler inventories to desirable levels. This process is estimated to have reduced diluted earnings per share by approximately $.29 in the first half of 2002 and is expected to continue impacting earnings through 2003. The company estimates that nearly half of the total earnings per share impact of this workdown was achieved in the first half of 2002.

What is the status of the company's major litigation matters?

The company is involved in several significant litigation matters, including those concerning TAXOL, BUSPAR, and average wholesale pricing. These cases involve allegations related to patent infringement, antitrust violations, consumer protection, and securities laws. The outcomes are uncertain and management states that if they do not prevail, the impact could be material. However, management's opinion is that a material adverse effect on operating results or financial position is unlikely.

How did the DuPont acquisition impact the company's financial performance in this period?

The DuPont Pharmaceuticals acquisition, completed in October 2001, contributed sales of $394 million in the second quarter of 2002 and $805 million in the first six months of 2002. It also led to increased research and development expenditures and contributed to the 'Other Healthcare' segment's earnings before income taxes. However, the acquisition's overall impact on the reported decline in earnings is secondary to the inventory workdown and generic competition issues.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2002

Summary

Bristol-Myers Squibb Company (BMY) reported a significant decrease in net earnings for the second quarter and first six months of 2002 compared to the prior year. This decline was primarily driven by a substantial reduction in sales, largely due to the ongoing workdown of U.S. wholesaler inventory levels and increased generic competition for key products like GLUCOPHAGE IR, TAXOL, and BUSPAR. The company also incurred significant expenses related to litigation and a substantial income tax payment. Despite the drop in earnings, BMY's financial position remains solid with a high level of working capital. The company is actively managing its inventory levels and has seen positive sales growth in its Nutritionals and Other Healthcare segments, as well as in international pharmaceutical markets. However, investors should remain aware of the ongoing impact of inventory adjustments and the significant legal and regulatory challenges facing the company, which could materially affect future results.

Key Highlights

1Net earnings for the six months ended June 30, 2002, were $1,025 million, a sharp decrease from $2,537 million in the same period of 2001.
2Worldwide sales for the six months decreased 13% to $8,135 million, primarily due to a 23% decline in domestic sales attributed to wholesaler inventory workdown and generic competition.
3The company incurred a pretax charge of $125 million for litigation expenses, including a settlement with Watson Pharmaceutical.
4A significant income tax payment of $1,755 million in the first six months of 2002 impacted cash flow from operations.
5Sales of key pharmaceuticals like GLUCOPHAGE IR, TAXOL, and BUSPAR saw dramatic declines due to loss of exclusivity and generic competition.
6The Nutritionals segment showed growth, with Enfamil sales increasing by 2% for the six-month period.
7The company is facing multiple significant litigation matters, including those related to TAXOL, BUSPAR, and average wholesale pricing, with uncertain outcomes that could have a material impact.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2002

Summary

Key Highlights

Frequently Asked Questions